9 Apr 2024

Cleveland Clinic, Tufts University Research Ties Gut Microbial TMAO Pathway to Chronic Kidney Disease

New findings from Cleveland Clinic and Tufts University researchers show high blood levels of TMAO (trimethylamine N-oxide) predicts future risk of developing chronic kidney disease over time.

Read More →
8 Nov 2023

A Novel, Small Molecule Inhibitor of Gut Microbial CutC Slows the Loss of Kidney Function in a Rat Model of CKD

Presented at ASN by Jerry Buysse, Robert Matunas, Camilla V. Simpson. Zehna Therapeutics Inc., San Francisco, CA, United States

Read More →
6 Sep 2023

Targeting Microbes to Treat Heart Disease

Deep in the recesses of the gut, they wait, ready to devour whatever comes their way. The microbes that live in the human intestines are not picky; their food is our food. But what we decide to eat — whether a greasy cheeseburger or a beet salad — determines not just the microbes’ health but our own.

Read More →
9 Jan 2023

Zehna Therapeutics to Present at Biotech Showcase™ 2023

Zehna Therapeutics will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023

Read More →
22 Nov 2022

Goodwill Fuels Innovation

With scientists and physicians seamlessly collaborating to provide the best patient care, Cleveland Clinic has been the future of health care since 1921. The academic medical center has established a new standard in medical research, made possible through philanthropic efforts.

Read More →
22 Apr 2022

Inside the Minds of Bioleaders – Camilla Simpson Interview

Camilla Simpson has over two decades of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career.

Read More →